Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca’s Enthusiasm For Vaccines On The Wane

As COVID-19 Nasal Vaccination Trial Falters

Oct 11 2022

• By Kevin Grogan

Nasal COVID-19 vaccine — • Source: Shutterstock

Related Content

AstraZeneca Unveils New Vaccines Division But Strategy Remains Unclear

Nov 10 2021

Sanofi and AZ’s RSV Antibody Gets EU Thumbs Up But Pfizer Rival Hot On Heels

Sep 16 2022

China Approves World’s First Inhaled COVID-19 Vaccine

Sep 09 2022

Bharat Biotech Debuts World’s First Exclusively Intranasal COVID-19 Vaccine

Sep 07 2022

Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure

Aug 29 2022

AstraZeneca’s Susan Galbraith On What’s Next In The Cancer Pipeline

Aug 17 2022

AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data

Jun 21 2022

Related Companies

AstraZeneca PLC

Pfizer Inc.

BioNTech SE

CanSino Biologics Inc.

Bharat Biotech

Moderna, Inc.

Daiichi Sankyo Co., Ltd.

Sanofi

Additional Topics

Vaccines Coronavirus COVID-19 Clinical Trials Research & Development Strategy BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window